Picture of Amplia Therapeutics logo

ATX — Amplia Therapeutics Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m+7.78%
3m-11.99%
6m-20.89%
1yr-48.66%
Volume Change (%)
10d/3m-38.36%
Price vs... (%)
52w High-50.91%
50d MA-2.61%
200d MA-17.68%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-24.5%
Return on Equity-25.12%
Operating Margin-215.42%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202231st Mar 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Amplia Therapeutics EPS forecast chart

Profile Summary

Amplia Therapeutics Limited is an Australia-based clinical-stage drug development company. The Company’s pipeline is developing two orally available small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its initial clinical development pipeline consists of AMP945 and AMP886 (FLT3/VEGFR3). The Company’s cancer program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its Fibrosis Program is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Its FAK inhibitors have been shown to block fibrosis in established animal models of both lung fibrosis and liver fibrosis (NASH).

Directors

Last Annual
March 31st, 2021
Last Interim
September 30th, 2021
Incorporated
October 11th, 2013
Public Since
December 23rd, 2013
No. of Employees
1
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
126,145,871.65

ATX Share Price Performance

FAQ

Or unlock with your email

Or unlock with your email